Clinical trials: SARS-CoV 2
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV (SNS812) in Healthy Participants
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled MBS-COV in Healthy Participants
- Trial name
- NCT05677893
- Testing
- MBS-COV
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Oneness Biotech Co., Ltd.
SARS CoV 2 Infection
Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2
This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study…
- Trial name
- NCT06283459
- Testing
- IMNN-101
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Imunon
COVID-19, Vaccine-Preventable Diseases
Impact of Reactogenicity of the 2024-2025 COVID-19 Vaccines on Health Care Workers and First Responders in the United States
To assess the impact of reactogenicity among health care workers and first responders receiving an updated 2024-25 Novavax COVID-19 vaccine as compared with those receiving an updated 2024-25 Pfizer-BioNTech mRNA COVID-19 vaccine
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Trial name
- SHIELD (NCT06633835)
- Testing
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Where
- United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novavax
COVID-19 Disease
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
An open label phase 2 trial to evaluate safety, tolerability and immunogenicity of the ABNCoV2 vaccine after intramuscular (IM) application.
- Trial name
- NCT05077267
- Testing
- ABNCoV2 100ug, ABNCoV2 50ug
- Where
- 2 sites in Germany
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
SARS CoV 2 Infection
The Efficacy and Safety of BioBlock® Intranasally Administered Virus-Neutralizing Bovine Colostrum Nasal Spray in Preventing of COVID-19 (Coronavirus Disease-19) Infection in Healthy Volunteer Individuals
This is a proof-of-concept double-blind cluster randomized (1:1) parallel study. The randomization unit is healthy volunteers who have no symptoms of COVID-19 at the start of the study and have not been infected with the…
- Trial name
- NCT05552950
- Testing
- BioBlock® antiviral nasal spray
- Where
- Estonia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Chemi-Pharm AS
SARS-CoV 2
Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
The study will be a randomized, partially-blinded, prime-boost, staggered dose-escalation Phase 1 study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three…
- Trial name
- NCT04450004
- Testing
- Intramuscular Vaccine
- Where
- 2 sites in Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID-19, SARS CoV 2 Infection
Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines
This is a Multi-Part, Phase 3, randomized, observer-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike…
- Trial name
- COVID-19 (NCT05372588)
- Testing
- NVX-CoV2515, NVX-Cov2373, NVX-CoV2373 + NVX-CoV2515
- Where
- 19 sites in Australia
- Volunteers
- 1,340 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
SARS CoV 2 Infection
Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects
This is a phase I, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of ASC10 tablets and an open-label, crossover design to evaluate the food effect on PK of ASC10 in…
- Trial name
- NCT05523141
- Testing
- ASC10
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Infections, Respiratory, Virus Diseases
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Originally, the study was planned to include two parts, i.e., Part A and Part B, however Part B was cancelled due to changes in the overall clinical development plan.
- Conditions
- Infections, Respiratory, Virus Diseases, Infection Viral, Vaccine Adverse Reaction
- Trial name
- NCT04380701
- Testing
- BNT162a1, BNT162b1, BNT162b2
- Where
- 5 sites in Germany
- Volunteers
- 512 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
Covid19, Coronavirus
QuadraMune(TM) for Prevention of COVID-19
QuadraMune(TM) is a nutritional supplement which has previously been demonstrated to possess antiinflammatory and immune modulatory activity based on in vitro and pilot in vivo studies.
- Conditions
- Covid19, Coronavirus, SARS-CoV 2
- Trial name
- NCT04421391
- Testing
- QuadraMune(TM)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Therapeutic Solutions International
Covid19, SARS CoV 2 Infection
Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19)
This is a first-in-human, phase I/IIa, randomized, controlled, observer-blinded, dose-escalation, multicentre clinical trial to evaluate safety and immunogenicity of COVID-19 HIPRA vaccine in adult healthy volunteers.
- Trial name
- NCT05007509
- Testing
- COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40
- Where
- 2 sites in Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Laboratorios Hipra, S.A.
Covid19, SARS-CoV Infection
A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults
This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2…
- Conditions
- Covid19, SARS-CoV Infection, Corona Virus Infection
- Trial name
- NCT04668339
- Testing
- ARCT-021 single dose priming, ARCT-021 two lower dose priming, ARCT-021 two higher dose priming
- Where
- 15 sites in United States, Singapore
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
Healthy Participants
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following…
- Trial name
- NCT05129475
- Testing
- PF-07321332/ritonavir, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2 Infection, COVID-19
Evaluation of Safety and Immunogenicity of the Recombinant ZR202-CoV and ZR202a-CoV Vaccines in Adults.
For Phase 1 only. Additional information will be provided when Phase 2 is implemented. This is a two-part phase I/II, single-center, observer-blind, randomized, controlled vaccine trial to evaluate the safety, reactogenicity, and…
- Trial name
- NCT05490108
- Testing
- ZR202-CoV, ZR202a-CoV, Comirnaty®
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
SARS CoV 2 Infection
Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age.
This is a Phase IIb, open-label, uncontrolled, multi-centre, non-inferiority clinical trial, to assess the safety and immunogenicity of BIMERVAX® as a heterologous booster dose in adolescents.
- Trial name
- NCT06234956
- Testing
- BIMERVAX
- Where
- 7 sites in Spain
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
COVID-19, SARS CoV 2 Infection
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous…
- Trial name
- NCT05605470
- Testing
- ChulaCov19 BNA159 vaccine (50 mcg), Pfizer/BNT vaccine (30 mcg), COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
- Where
- 5 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Technovalia, Pty Ltd
Covid19 Vaccine
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents
The purpose of this study is to assess the safety and immunogenicity of MVC-COV1901 vaccine compared to placebo in participants aged ≥ 12 to < 18 years.
- Trial name
- NCT04951388
- Testing
- MVC-COV1901(S protein with adjuvant), MVC-COV1901(Saline)
- Where
- 5 sites in Taiwan
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.